# A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy

> **NCT03122522** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 70 (actual)

## Conditions studied

- Metastatic Melanoma

## Interventions

- **DRUG:** ipilimumab
- **DRUG:** nivolumab

## Key facts

- **NCT ID:** NCT03122522
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-04-17
- **Primary completion:** 2027-04
- **Final completion:** 2027-04
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2026-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03122522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03122522, "A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03122522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*